User profiles for J. Corvol

jean-christophe corvol

Sorbonne université, Assistance Publique Hôpitaux de Paris, Inserm, Paris Brain Institute
Verified email at aphp.fr
Cited by 28015

European academy of neurology/movement disorder society‐European section guideline on the treatment of Parkinson's disease: I. Invasive therapies

…, JC Corvol, G Fabbrini, J Ferreira… - European journal of …, 2022 - Wiley Online Library
J.-C. Corvol received honoraria for talks sponsored by Ever Pharma. J. Ferreira reports
grants from Abbvie, Novartis, Medtronic, and Fundação MSD. He received payment for lectures …

[HTML][HTML] Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects

AM Bonnet, MF Jutras, V Czernecki, JC Corvol… - Parkinson's …, 2012 - hindawi.com
Nonmotor symptoms (NMSs) of Parkinson’s disease (PD) are common, but they are often
underrecognized in clinical practice, because of the lack of spontaneous complaints by the …

Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials

JC Corvol, A Bouzamondo, M Sirol… - Archives of internal …, 2003 - jamanetwork.com
Background Previous overviews suggested that hydroxymethyl glutaryl coenzyme A
reductase inhibitors (statins), but not other lipid-lowering therapy (LLT), may reduce stroke …

Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria

…, J Kassubek, JC Corvol, JL Whitwell, J Levin… - Movement …, 2017 - Wiley Online Library
Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

…, M Martinez, JC Corvol, S Lesage, J Jankovic… - The Lancet …, 2019 - thelancet.com
Background Genome-wide association studies (GWAS) in Parkinson's disease have increased
the scope of biological knowledge about the disease over the past decade. We aimed to …

Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum

…, JC Corvol, A Stipanovich, J Caboche… - Proceedings of the …, 2005 - National Acad Sciences
Many drugs of abuse exert their addictive effects by increasing extracellular dopamine in
the nucleus accumbens, where they likely alter the plasticity of corticostriatal glutamatergic …

Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties

E Valjent, JC Corvol, C Pagès, MJ Besson… - Journal of …, 2000 - Soc Neuroscience
A central feature of drugs of abuse is to induce gene expression in discrete brain structures
that are critically involved in behavioral responses related to addictive processes. Although …

Targeting chelatable iron as a therapeutic modality in Parkinson's disease

…, N Zahr, A Destée, JC Corvol… - Antioxidants & redox …, 2014 - liebertpub.com
Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …

[PDF][PDF] Loss of VPS13C function in autosomal-recessive parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-dependent mitophagy

…, F Tison, C Tranchant, M Vidailhet, JC Corvol… - The American Journal of …, 2016 - cell.com
Autosomal-recessive early-onset parkinsonism is clinically and genetically heterogeneous.
The genetic causes of approximately 50% of autosomal-recessive early-onset forms of …

[HTML][HTML] Trial of deferiprone in Parkinson's disease

…, J Labreuche, O Rascol, JC Corvol… - … England Journal of …, 2022 - Mass Medical Soc
Background Iron content is increased in the substantia nigra of persons with Parkinson’s
disease and may contribute to the pathophysiology of the disorder. Early research suggests that …